Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT204
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
MT204 is a humanized IgG1 monoclonal antibody that targets interleukin-2 (IL-2). It functions by preventing soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocking CD25-bound IL-2 on high-affinity IL-2 receptors. This dual mechanism of action results in potent anti-proliferative activity against natural killer (NK) cells and natural killer lymphoma (NKL) cells. Preclinical studies in rhesus monkeys using allogeneic skin graft models have demonstrated that MT204 possesses significant immunosuppressive activity and is well-tolerated, suggesting its potential application in transplantation medicine and the treatment of lymphoproliferative disorders.
02
Targets
IL-2 (Interleukin 2)
Beyond the preview
Go deeper on MT204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT204.